APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tuberculosis Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Tuberculosis Vaccine Market Outlook and Growth Opportunities 2026

29 December 2025192 pages

Choose your research edition.

Industry ResearchTuberculosis Vaccine Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Tuberculosis Vaccine Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Tuberculosis Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tuberculosis Vaccine Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Tuberculosis Vaccine Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Tuberculosis Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Tuberculosis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tuberculosis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tuberculosis Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Tuberculosis Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Tuberculosis Vaccine market include AJ Vaccines, Ataulpho de Paiva, BioFarma, Biomed Lublin, GreenSignal Bio Pharma, IVAC, Japan BCG Lab, Microgen and Queen Saovabha Mem. Inst, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Tuberculosis Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tuberculosis Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tuberculosis Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tuberculosis Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Tuberculosis Vaccine Segment by Company

AJ Vaccines

Ataulpho de Paiva

BioFarma

Biomed Lublin

GreenSignal Bio Pharma

IVAC

Japan BCG Lab

Microgen

Queen Saovabha Mem. Inst

Serum Institute of India

Taj Pharmaceuticals

Merck

China National Biotec

Tuberculosis Vaccine Segment by Type

Immune Vaccine

Therapy Vaccine

Tuberculosis Vaccine Segment by Application

Self-Procurement

UNICEF

Other

Tuberculosis Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Tuberculosis Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Tuberculosis Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Tuberculosis Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Tuberculosis Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tuberculosis Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tuberculosis Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tuberculosis Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tuberculosis Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tuberculosis Vaccine industry.

Chapter 3: Detailed analysis of Tuberculosis Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Tuberculosis Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Tuberculosis Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Tuberculosis Vaccine Industry Trends Table 2. Tuberculosis Vaccine Industry Drivers Table 3. Tuberculosis Vaccine Industry Opportunities and Challenges Table 4. Tuberculosis Vaccine Industry Restraints Table 5. Global Tuberculosis Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Tuberculosis Vaccine Revenue Share by Company (2021-2026) Table 7. Global Tuberculosis Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Tuberculosis Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Tuberculosis Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Tuberculosis Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Tuberculosis Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Tuberculosis Vaccine Company, Product Type & Application Table 13. Global Tuberculosis Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Tuberculosis Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Immune Vaccine Table 18. Significant Companies of Therapy Vaccine Table 19. Global Tuberculosis Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Tuberculosis Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Tuberculosis Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Tuberculosis Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Tuberculosis Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Tuberculosis Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Tuberculosis Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Tuberculosis Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Tuberculosis Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Tuberculosis Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Self-Procurement Table 30. Significant Companies of UNICEF Table 31. Significant Companies of Other Table 32. Global Tuberculosis Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Tuberculosis Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Tuberculosis Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Tuberculosis Vaccine Sales Volume Share by Application (2021-2026) Table 36. Global Tuberculosis Vaccine Sales Volume Share by Application (2027-2032) Table 37. Global Tuberculosis Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Tuberculosis Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Tuberculosis Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Tuberculosis Vaccine Sales Value Share by Application (2021-2026) Table 41. Global Tuberculosis Vaccine Sales Value Share by Application (2027-2032) Table 42. Global Tuberculosis Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Tuberculosis Vaccine Sales by Region (2021-2026) & (K Units) Table 44. Global Tuberculosis Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Tuberculosis Vaccine Sales by Region (2027-2032) & (K Units) Table 46. Global Tuberculosis Vaccine Sales Market Share by Region (2027-2032) Table 47. Global Tuberculosis Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Tuberculosis Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Tuberculosis Vaccine Sales Value Share by Region (2021-2026) Table 50. Global Tuberculosis Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Tuberculosis Vaccine Sales Value Share by Region (2027-2032) Table 52. Global Tuberculosis Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Tuberculosis Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Tuberculosis Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Tuberculosis Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Tuberculosis Vaccine Sales by Country (2021-2026) & (K Units) Table 57. Global Tuberculosis Vaccine Sales Market Share by Country (2021-2026) Table 58. Global Tuberculosis Vaccine Sales by Country (2027-2032) & (K Units) Table 59. Global Tuberculosis Vaccine Sales Market Share by Country (2027-2032) Table 60. Global Tuberculosis Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Tuberculosis Vaccine Sales Value Market Share by Country (2021-2026) Table 62. Global Tuberculosis Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Tuberculosis Vaccine Sales Value Market Share by Country (2027-2032) Table 64. AJ Vaccines Company Information Table 65. AJ Vaccines Business Overview Table 66. AJ Vaccines Tuberculosis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. AJ Vaccines Tuberculosis Vaccine Product Portfolio Table 68. AJ Vaccines Recent Development Table 69. Ataulpho de Paiva Company Information Table 70. Ataulpho de Paiva Business Overview Table 71. Ataulpho de Paiva Tuberculosis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Ataulpho de Paiva Tuberculosis Vaccine Product Portfolio Table 73. Ataulpho de Paiva Recent Development Table 74. BioFarma Company Information Table 75. BioFarma Business Overview Table 76. BioFarma Tuberculosis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. BioFarma Tuberculosis Vaccine Product Portfolio Table 78. BioFarma Recent Development Table 79. Biomed Lublin Company Information Table 80. Biomed Lublin Business Overview Table 81. Biomed Lublin Tuberculosis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Biomed Lublin Tuberculosis Vaccine Product Portfolio Table 83. Biomed Lublin Recent Development Table 84. GreenSignal Bio Pharma Company Information Table 85. GreenSignal Bio Pharma Business Overview Table 86. GreenSignal Bio Pharma Tuberculosis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. GreenSignal Bio Pharma Tuberculosis Vaccine Product Portfolio Table 88. GreenSignal Bio Pharma Recent Development Table 89. IVAC Company Information Table 90. IVAC Business Overview Table 91. IVAC Tuberculosis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. IVAC Tuberculosis Vaccine Product Portfolio Table 93. IVAC Recent Development Table 94. Japan BCG Lab Company Information Table 95. Japan BCG Lab Business Overview Table 96. Japan BCG Lab Tuberculosis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Japan BCG Lab Tuberculosis Vaccine Product Portfolio Table 98. Japan BCG Lab Recent Development Table 99. Microgen Company Information Table 100. Microgen Business Overview Table 101. Microgen Tuberculosis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Microgen Tuberculosis Vaccine Product Portfolio Table 103. Microgen Recent Development Table 104. Queen Saovabha Mem. Inst Company Information Table 105. Queen Saovabha Mem. Inst Business Overview Table 106. Queen Saovabha Mem. Inst Tuberculosis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Queen Saovabha Mem. Inst Tuberculosis Vaccine Product Portfolio Table 108. Queen Saovabha Mem. Inst Recent Development Table 109. Serum Institute of India Company Information Table 110. Serum Institute of India Business Overview Table 111. Serum Institute of India Tuberculosis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Serum Institute of India Tuberculosis Vaccine Product Portfolio Table 113. Serum Institute of India Recent Development Table 114. Taj Pharmaceuticals Company Information Table 115. Taj Pharmaceuticals Business Overview Table 116. Taj Pharmaceuticals Tuberculosis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Taj Pharmaceuticals Tuberculosis Vaccine Product Portfolio Table 118. Taj Pharmaceuticals Recent Development Table 119. Merck Company Information Table 120. Merck Business Overview Table 121. Merck Tuberculosis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Merck Tuberculosis Vaccine Product Portfolio Table 123. Merck Recent Development Table 124. China National Biotec Company Information Table 125. China National Biotec Business Overview Table 126. China National Biotec Tuberculosis Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. China National Biotec Tuberculosis Vaccine Product Portfolio Table 128. China National Biotec Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Tuberculosis Vaccine Distributors List Table 132. Tuberculosis Vaccine Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Tuberculosis Vaccine Product Image Figure 2. Global Tuberculosis Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tuberculosis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Tuberculosis Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Tuberculosis Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Tuberculosis Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Immune Vaccine Image Figure 10. Therapy Vaccine Image Figure 11. Global Tuberculosis Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Tuberculosis Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Tuberculosis Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Tuberculosis Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Tuberculosis Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Tuberculosis Vaccine Sales Value Share by Type (2021-2032) Figure 17. Self-Procurement Image Figure 18. UNICEF Image Figure 19. Other Image Figure 20. Global Tuberculosis Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Tuberculosis Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Tuberculosis Vaccine Sales Volume Share by Application (2021-2032) Figure 23. Global Tuberculosis Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Tuberculosis Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Tuberculosis Vaccine Sales Value Share by Application (2021-2032) Figure 26. Global Tuberculosis Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Tuberculosis Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Tuberculosis Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Tuberculosis Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Tuberculosis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 31. North America Tuberculosis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Tuberculosis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Tuberculosis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Tuberculosis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Tuberculosis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Tuberculosis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. South America Tuberculosis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Tuberculosis Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Tuberculosis Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Tuberculosis Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Tuberculosis Vaccine Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Tuberculosis Vaccine Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Immune Vaccine
  • Therapy Vaccine
Applications
  • Self-Procurement
  • UNICEF
  • Other
Companies covered
  • AJ Vaccines
  • Ataulpho de Paiva
  • BioFarma
  • Biomed Lublin
  • GreenSignal Bio Pharma
  • IVAC
  • Japan BCG Lab
  • Microgen
  • Queen Saovabha Mem. Inst
  • Serum Institute of India
  • Taj Pharmaceuticals
  • Merck
  • China National Biotec

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Tuberculosis Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Tuberculosis Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Tuberculosis Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Tuberculosis Vaccine Market Dynamics
  1. 2.1 Tuberculosis Vaccine Industry Trends
  2. 2.2 Tuberculosis Vaccine Industry Drivers
  3. 2.3 Tuberculosis Vaccine Industry Opportunities and Challenges
  4. 2.4 Tuberculosis Vaccine Industry Restraints
3 Tuberculosis Vaccine Market by Company
  1. 3.1 Global Tuberculosis Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Tuberculosis Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Tuberculosis Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Tuberculosis Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Tuberculosis Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Tuberculosis Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Tuberculosis Vaccine Company Product Type and Application
  8. 3.8 Global Tuberculosis Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Tuberculosis Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Tuberculosis Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Tuberculosis Vaccine Market by Type
  1. 4.1 Tuberculosis Vaccine Type Introduction
  2. 4.1.1 Immune Vaccine
  3. 4.1.2 Therapy Vaccine
  4. 4.2 Global Tuberculosis Vaccine Sales Volume by Type
  5. 4.2.1 Global Tuberculosis Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Tuberculosis Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Tuberculosis Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Tuberculosis Vaccine Sales Value by Type
  9. 4.3.1 Global Tuberculosis Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Tuberculosis Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Tuberculosis Vaccine Sales Value Share by Type (2021-2032)
5 Tuberculosis Vaccine Market by Application
  1. 5.1 Tuberculosis Vaccine Application Introduction
  2. 5.1.1 Self-Procurement
  3. 5.1.2 UNICEF
  4. 5.1.3 Other
  5. 5.2 Global Tuberculosis Vaccine Sales Volume by Application
  6. 5.2.1 Global Tuberculosis Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Tuberculosis Vaccine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Tuberculosis Vaccine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Tuberculosis Vaccine Sales Value by Application
  10. 5.3.1 Global Tuberculosis Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Tuberculosis Vaccine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Tuberculosis Vaccine Sales Value Share by Application (2021-2032)
6 Tuberculosis Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Tuberculosis Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tuberculosis Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Tuberculosis Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Tuberculosis Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Tuberculosis Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Tuberculosis Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Tuberculosis Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Tuberculosis Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Tuberculosis Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Tuberculosis Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Tuberculosis Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Tuberculosis Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Tuberculosis Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Tuberculosis Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Tuberculosis Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Tuberculosis Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Tuberculosis Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Tuberculosis Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Tuberculosis Vaccine Sales Value Share by Country, 2025 VS 2032
7 Tuberculosis Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Tuberculosis Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Tuberculosis Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Tuberculosis Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Tuberculosis Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Tuberculosis Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Tuberculosis Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Tuberculosis Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Tuberculosis Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Tuberculosis Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Tuberculosis Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Tuberculosis Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AJ Vaccines
  2. 8.1.1 AJ Vaccines Company Information
  3. 8.1.2 AJ Vaccines Business Overview
  4. 8.1.3 AJ Vaccines Tuberculosis Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AJ Vaccines Tuberculosis Vaccine Product Portfolio
  6. 8.1.5 AJ Vaccines Recent Developments
  7. 8.2 Ataulpho de Paiva
  8. 8.2.1 Ataulpho de Paiva Company Information
  9. 8.2.2 Ataulpho de Paiva Business Overview
  10. 8.2.3 Ataulpho de Paiva Tuberculosis Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Ataulpho de Paiva Tuberculosis Vaccine Product Portfolio
  12. 8.2.5 Ataulpho de Paiva Recent Developments
  13. 8.3 BioFarma
  14. 8.3.1 BioFarma Company Information
  15. 8.3.2 BioFarma Business Overview
  16. 8.3.3 BioFarma Tuberculosis Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 BioFarma Tuberculosis Vaccine Product Portfolio
  18. 8.3.5 BioFarma Recent Developments
  19. 8.4 Biomed Lublin
  20. 8.4.1 Biomed Lublin Company Information
  21. 8.4.2 Biomed Lublin Business Overview
  22. 8.4.3 Biomed Lublin Tuberculosis Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Biomed Lublin Tuberculosis Vaccine Product Portfolio
  24. 8.4.5 Biomed Lublin Recent Developments
  25. 8.5 GreenSignal Bio Pharma
  26. 8.5.1 GreenSignal Bio Pharma Company Information
  27. 8.5.2 GreenSignal Bio Pharma Business Overview
  28. 8.5.3 GreenSignal Bio Pharma Tuberculosis Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 GreenSignal Bio Pharma Tuberculosis Vaccine Product Portfolio
  30. 8.5.5 GreenSignal Bio Pharma Recent Developments
  31. 8.6 IVAC
  32. 8.6.1 IVAC Company Information
  33. 8.6.2 IVAC Business Overview
  34. 8.6.3 IVAC Tuberculosis Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 IVAC Tuberculosis Vaccine Product Portfolio
  36. 8.6.5 IVAC Recent Developments
  37. 8.7 Japan BCG Lab
  38. 8.7.1 Japan BCG Lab Company Information
  39. 8.7.2 Japan BCG Lab Business Overview
  40. 8.7.3 Japan BCG Lab Tuberculosis Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Japan BCG Lab Tuberculosis Vaccine Product Portfolio
  42. 8.7.5 Japan BCG Lab Recent Developments
  43. 8.8 Microgen
  44. 8.8.1 Microgen Company Information
  45. 8.8.2 Microgen Business Overview
  46. 8.8.3 Microgen Tuberculosis Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Microgen Tuberculosis Vaccine Product Portfolio
  48. 8.8.5 Microgen Recent Developments
  49. 8.9 Queen Saovabha Mem. Inst
  50. 8.9.1 Queen Saovabha Mem. Inst Company Information
  51. 8.9.2 Queen Saovabha Mem. Inst Business Overview
  52. 8.9.3 Queen Saovabha Mem. Inst Tuberculosis Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Queen Saovabha Mem. Inst Tuberculosis Vaccine Product Portfolio
  54. 8.9.5 Queen Saovabha Mem. Inst Recent Developments
  55. 8.10 Serum Institute of India
  56. 8.10.1 Serum Institute of India Company Information
  57. 8.10.2 Serum Institute of India Business Overview
  58. 8.10.3 Serum Institute of India Tuberculosis Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Serum Institute of India Tuberculosis Vaccine Product Portfolio
  60. 8.10.5 Serum Institute of India Recent Developments
  61. 8.11 Taj Pharmaceuticals
  62. 8.11.1 Taj Pharmaceuticals Company Information
  63. 8.11.2 Taj Pharmaceuticals Business Overview
  64. 8.11.3 Taj Pharmaceuticals Tuberculosis Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Taj Pharmaceuticals Tuberculosis Vaccine Product Portfolio
  66. 8.11.5 Taj Pharmaceuticals Recent Developments
  67. 8.12 Merck
  68. 8.12.1 Merck Company Information
  69. 8.12.2 Merck Business Overview
  70. 8.12.3 Merck Tuberculosis Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Merck Tuberculosis Vaccine Product Portfolio
  72. 8.12.5 Merck Recent Developments
  73. 8.13 China National Biotec
  74. 8.13.1 China National Biotec Company Information
  75. 8.13.2 China National Biotec Business Overview
  76. 8.13.3 China National Biotec Tuberculosis Vaccine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 China National Biotec Tuberculosis Vaccine Product Portfolio
  78. 8.13.5 China National Biotec Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Tuberculosis Vaccine Value Chain Analysis
  2. 9.1.1 Tuberculosis Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Tuberculosis Vaccine Sales Mode & Process
  6. 9.2 Tuberculosis Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Tuberculosis Vaccine Distributors
  9. 9.2.3 Tuberculosis Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst